PCSA (Processa Pharmaceuticals) Insider Ownership: 24.50 % (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCSA Processa Pharmaceuticals Inc PCSA
29 GF Score
Price $2.30
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Insider Ownership?

Processa Pharmaceuticals PCSA +2.85% 29 Insider Ownership is 24.50 % as of Jul. 20, 2026. GuruFocus rates PCSA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Processa Pharmaceuticals's insider ownership is 24.50%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Processa Pharmaceuticals's Institutional Ownership is 7.32%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Processa Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 85.69%.

Processa Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Insider Ownership Chart

Processa Pharmaceuticals Historical Data

The historical data trend for Processa Pharmaceuticals can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 4.59 4.59 2.39 2.39 2.39 2.39 53.08 39.72 24.67 24.50
PCSA
29GF Score
Processa Pharmaceuticals Inc PCSA
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 24.50 % mean?
Processa Pharmaceuticals (PCSA) has a Insider Ownership of 24.50 % as of Jul. 20, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Processa Pharmaceuticals and its competitors.
Is Processa Pharmaceuticals' Insider Ownership too high?
Processa Pharmaceuticals' current Insider Ownership is 24.50 %. Overall, Processa Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' Insider Ownership compare to ELAB and MBIO?
Processa Pharmaceuticals' Insider Ownership of 24.50 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current Insider Ownership is 24.50 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current Insider Ownership of 24.50 %. The current Insider Ownership is 24.50 %. Processa Pharmaceuticals' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Insider Ownership is 24.50 % as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
29GF Score

Get the complete analysis for PCSA

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.30
Price